Regentis Biomaterials Ltd. (RGNT)
| Market Cap | 11.50M |
| Revenue (ttm) | n/a |
| Net Income | -13.69M |
| EPS | -24.16 |
| Shares Out | 5.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,567 |
| Open | 2.202 |
| Previous Close | 2.280 |
| Day's Range | 2.010 - 2.350 |
| 52-Week Range | 2.010 - 8.350 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About RGNT
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
Financial Performance
Financial StatementsNews
Regentis Biomaterials enters collaboration with Humanitas Research Hospital
Regentis Biomaterials (RGNT) announced a collaboration with Humanitas Research Hospital in Milan, Italy,. This collaboration is currently in the process of being formalized, is expected to support the...
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of Excellenc...
Regentis Biomaterials develops and patents solvent-free manufacturing process
Regentis Biomaterials (RGNT) has developed a new manufacturing process for its lead product, GelrinC, an off-the-shelf hydrogel synchronized erosion and resorbable implant for the treatment of painful...
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is pending...
Regentis Biomaterials initiated with a Buy at ThinkEquity
ThinkEquity initiated coverage of Regentis Biomaterials (RGNT) with a Buy rating and $10 price target Regentis is a single-asset medtech company advancing GelrinC for focal knee cartilage defects, the...
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinC Already approved in Europe, GelrinC is expe...
Regentis Biomaterials appoints Galit Reke as CMO
Regentis Biomaterials (RGNT) announced the appointment of Dr. Galit Reske as Chief Medical Officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy, and global clini...
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition HE...
Regentis Biomaterials expands European clinical site network
Regentis Biomaterials (RGNT) announced the expansion of its European clinical site network into new countries, strengthening its infrastructure to support both ongoing clinical programs including its ...
Regentis Biomaterials appoints Ori Gon as CFO, CBO
Regentis Biomaterials (RGNT) announced the appointment of Ori Gon as CFO and CBO. Gon will lead the Company’s commercial and business development activities, as well as its financial strategy, plannin...
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S. Ori Gon brings substantial...
Regentis Biomaterials expanding Phase III GelrinC clinical site network
Regentis Biomaterials (RGNT) announced the expansion of its U.S. clinical site network, further strengthening its infrastructure to support its ongoing pivotal Phase III study of GelrinC for knee cart...
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs GelrinC is set to transform cartilage repair market wit...
Regentis Biomaterials Ltd trading resumes
11:24 EST Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, volatility trading pause
11:04 EST Regentis Biomaterials (RGNT) Ltd trading halted, volatility trading pause
Regentis Biomaterials announces long-term imaging data on GelrinC
Regentis Biomaterials (RGNT) announced new long-term imaging data from its completed European clinical trial of GelrinC, demonstrating that regenerated cartilage exhibits internal structural organizat...
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint function This...
Regentis Biomaterials Ltd trading resumes
11:01 EST Regentis Biomaterials (RGNT) Ltd trading resumes
Regentis Biomaterials Ltd trading halted, volatility trading pause
10:56 EST Regentis Biomaterials (RGNT) Ltd trading halted, volatility trading pause
Regentis Biomaterials announces publication of GelrinC follow-up results
Regentis Biomaterials (RGNT) announced publication of long-term follow-up results from its successfully concluded Phase II clinical trial of GelrinC in the peer-reviewed journal Cartilage. The study, ...
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint New peer-reviewed data published in the scientif...
Regentis Biomaterials granted U.S. patent for GelrinC
Regentis Biomaterials (RGNT) announced that the U.S. Patent and Trademark Office has issued the Company a patent titled “Organic Solvent Free Compositions Compromising Protein-Polymer Conjugates and U...
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedure Robust IP portfolio includes 35 issued patents to date w...
Opening Day: Regentis Biomaterials raises $10M in IPO
Regentis Biomaterials has completed its initial public offering, issuing 1,250,000 ordinary shares at $8.00 each. The offering generated $10M in gross proceeds before underwriting fees and expenses. L...
Regentis Biomaterials commences trading on NYSE
Regentis Biomaterials (RGNT) is now trading on the NYSE American under the symbol “RGNT”. Regentis’ lead product, GelrinC, is a cell-free, off-the-shelf hydrogel synchronized erosion and resorbable im...